White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...
Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...
In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst ...
Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...
UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...
Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...
In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning ...
FDA label expansion adds relapse-prevention in adult schizophrenia, addressing a major driver of hospitalization, functional ...
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...
Natalie de Graaf is VP and GM of Data, AI and ML; Solutions for Health and National Security at the API Innovation Center. Natalie de Graaf, from the API Innovation Center, discusses a recent ...
There are two main changes required to break the operational cost barrier. The first is technology-enabled automation. By ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results